BioBehavioral Diagnostics Co.: Series B $10M

Posted in I - Series B, Q - 1Q10, R - NORTH EAST, X - ADHD, X - Device (Diagnostic), XX - MA

BioBehavioral Diagnostics (Westford, MA) a commercial-stage diagnostics company focused on the Quotient™ ADHD System for the objective and accurate assessment of attention-deficit hyperactivity disorder, closed a $10M Series B financing. Participants include Sevin Rosen Funds and Tullis Health Investors.

Oct

2009

Curemark, Inc.: Series A $6.5M

Posted in I - Series A, Q - 3Q09, R - NORTH EAST, X - ADHD, X - CNS, XX - NY

Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.

Feb

2007

BioBehavioral Diagnostics: Series A $8.5M

Posted in I - Series A, R - NORTH EAST, X - ADHD

BioBehavioral Diagnostics (Cambridge, MA) a developer of a diagnostic system for measuring the core components of Attention Deficit Hyperactivity Disorder closed a $8.5M Series A financing. The deal was led by Sevin Rosen Funds and Tullis-Dickerson.

to top of page...